Intrasense S.A. develops and markets AI-enhanced medical imaging software solutions that facilitate diagnosis, decision-making, and therapeutic follow-up for healthcare professionals worldwide; its core offerings include the Myrian platform, a multimodal advanced visualization tool with clinical applications and artificial intelligence algorithms for pathologies such as prostate, lung, brain, liver lesions, pancreatic cancer, and bone lesions; the Lifow platform, an oncology-focused solution that automates lesion identification and measurement to support multidisciplinary patient care; and related services encompassing software installation, maintenance, rental, and support. Founded in 2004 and headquartered in Montpellier, France, the company operates in over 40 countries with approximately 1,200 customers and maintains a presence including offices in Europe, the United States, Germany, and China. As a subsidiary of Guerbet Group following the 2023 acquisition of a majority stake through a capital increase and tender offer, Intrasense benefits from strategic synergies including a licensing agreement integrating Guerbet's AI algorithms into its platforms; recent developments encompass CE marking under MDR for Myrian 2.14 in 2025, a new strategic roadmap emphasizing innovation, product expansion, and geographic growth, alongside H1 2025 revenue growth of 33% to €1.6 million driven by European sales.